Spark Therapeutics (NASDAQ:ONCE) was downgraded by research analysts at Chardan Capital from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. They currently have a $85.00 price target on the biotechnology company’s stock, up from their previous price target of $80.00. Chardan Capital’s price objective indicates a potential upside of 12.76% from the stock’s current price.
A number of other analysts also recently issued reports on the stock. SunTrust Banks lifted their price target on shares of Spark Therapeutics to $113.00 and gave the company a “buy” rating in a report on Thursday, January 4th. ValuEngine downgraded shares of Spark Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Credit Suisse Group initiated coverage on shares of Spark Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 price target on the stock. Wedbush downgraded shares of Spark Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $50.00 to $35.00 in a report on Tuesday, January 16th. Finally, Barclays reiterated a “buy” rating and issued a $64.00 price target (up from $61.00) on shares of Spark Therapeutics in a report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $71.89.
Shares of ONCE stock opened at $75.38 on Monday. The firm has a market cap of $3,029.13, a PE ratio of -9.88 and a beta of 2.55. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.73). The company had revenue of $7.41 million for the quarter, compared to the consensus estimate of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. analysts anticipate that Spark Therapeutics will post -3.33 earnings per share for the current fiscal year.
In other Spark Therapeutics news, COO John Furey sold 13,277 shares of Spark Therapeutics stock in a transaction on Wednesday, April 18th. The shares were sold at an average price of $82.52, for a total value of $1,095,618.04. Following the completion of the transaction, the chief operating officer now directly owns 2,277 shares of the company’s stock, valued at approximately $187,898.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 40,000 shares of company stock valued at $3,200,466 over the last three months. Corporate insiders own 7.30% of the company’s stock.
Several large investors have recently modified their holdings of the business. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Spark Therapeutics during the 4th quarter worth about $28,188,000. Rockefeller Financial Services Inc. boosted its stake in shares of Spark Therapeutics by 27,905.0% during the 4th quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock worth $18,202,000 after purchasing an additional 352,719 shares during the period. OppenheimerFunds Inc. purchased a new position in shares of Spark Therapeutics during the 4th quarter worth about $11,249,000. Macquarie Group Ltd. purchased a new position in shares of Spark Therapeutics during the 4th quarter worth about $9,012,000. Finally, Spark Investment Management LLC purchased a new position in shares of Spark Therapeutics during the 4th quarter worth about $8,833,000.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/25/spark-therapeutics-once-lowered-to-neutral-at-chardan-capital.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.